Europe, 22-10-2025 — Global Health Technology Assessment: The European Commission’s Health & Food Safety directorate published a newsletter on 17 October announcing that it has adopted the procedural rules for Joint Clinical Assessments (JCAs) of medical devices and IVDs under the EU Health Technology Assessment Regulation (HTAR). The item also points to the Commission’s hub for HTA implementation and EUR-Lex for the base law (Regulation (EU) 2021/2282)
The EU is building a single scientific assessment of clinical evidence for (selected) devices/IVDs at EU level, which national HTA bodies can use for pricing/reimbursement decisions. It doesn’t replace CE-marking (MDR/IVDR) and it doesn’t set prices, but it aims to end duplicative clinical evidence reviews across 27 countries.The Commission’s explainer on JCAs
Where the EU is right now
- The legal support: HTAR entered into force in 2022 and applies from 12 January 2025. Commission’s implementation
- JCAs so far have focused on medicines, but the Commission has now adopted rules for device/IVD JCAs and previously adopted rules for joint scientific consultations (JSCs).
- Ongoing JCA topics (currently medicines). medicines-specific JCA, EMA overview of the new rules becoming effective and planned numbers of JSCs (including for devices)
The European Union other moving pieces you can’t ignore
MDR/IVDR remain the regulatory gates (safety/performance + CE marking). MDR and IVDR Expert Panels that advise on major clinical evaluations (MDR Art. 106 / IVDR Art. 48(6).
How other jurisdictions line up (regulation vs. HTA vs. payment)
United States
FDA authorizes devices (510(k), De Novo, PMA). Evidence frameworks increasingly embrace RWE (device RWE guidance) benefit-risk. CMS decides Medicare coverage via NCD/LCD; when data are immature, Coverage with Evidence Development (CED) can conditionally cover while studies run. overview of the NCD process, CMS also launched TCET (a pathway to speed coverage for certain FDA Breakthrough devices). Unlike the EU’s JCA, the U.S. splits “authorization” (FDA) from “coverage” (CMS/private payers).
Canada
Medical Device Single Audit Program( MDSAP ) is mandatory for licensed manufacturers — background and transition and Medical Device Single Audit Program (MDSAP) Transition Plan. Canada’s regulatory-HTA coordination (e.g., aligned reviews) is conceptually close to the EU’s ambition to reduce duplication via JCAs.
Australia
TGA device framework overview and Australian Regulatory Guidelines for Medical Devices (ARGMD). MSAC evaluates procedures/technologies for funding (process) the Prescribed List (formerly “Prostheses List”) governs private insurer benefits for devices (latest list + reform timeline) and reform status. Australia runs a well-documented, committee-led HTA model (MSAC/MDHTAC) that sits after TGA authorization—again echoing the EU split of regulatory and HTA/pricing tracks.
Japan
Since 2016, MHLW has applied cost-effectiveness evaluation to price adjustments for certain drugs/devices; peer-reviewed summary and Government English portals are limited; Japan couples PMDA approval with a central price-setting process that can apply HTA-style cost-effectiveness to reimbursement prices, a different lever than the EU’s JCA, but similar end goal: value-based spending.
Singapore (a clear HTA/regulatory split in Asia)
ACE (Agency for Care Effectiveness) is the national HTA body — who they are methods/process and HTA outputs for medical technologies Singapore’s centralized HTA (ACE) informs government funding/subsidy decisions separately from HSA authorization—very analogous to how EU members will use JCAs within national reimbursement pathways.
Africa (regulatory integration rising; HTA capacity growing)
The African Medicines Agency (AMA) treaty entered into force in 2021 and the AU appointed its first Director-General in 2025. AU press release and appointment. AUDA-NEPAD AMA explainer – AMA will be established as a Specialized Agency of the African Union (AU) dedicated to improving access to quality, safe and efficacious medical products in Africa.
Where does the Medical Device Single Audit Program fit in?
EU JCAs are about clinical value assessment for coverage/pricing. MDSAP is about quality system auditing (manufacturing compliance) across the U.S., Canada, Japan, Australia, and Brazil. For the official background IMDRF MDSAP. FDA summary and document set. Canada requires MDSAP certification for licensed manufacturers (see Canada’s transition/completion notice)
MDSAP ≠ HTA. It can de-risk regulatory submissions and inspections across markets, but it won’t satisfy evidence demands for EU JCAs, CMS coverage, MSAC decisions, ACE technology guidances, or CADTH reviews.
Major EU countries participating in Joint Clinical Assessment (JCAs)
Design your trials for comparative value, not just safety/performance. The JCA clinical questions will look a lot like IQWiG/HAS-style relative-effectiveness questions. Start with the Commission’s JCA FAQ and JSC factsheet for early advice.
Bridge evidence across markets.
- EU: plan for JCAs;
- U.S.: anticipate CMS CED/TCET needs Coverage with Evidence Development
- Canada: consider aligned reviews and CADTH methods
- Australia: work MSAC’s PICO-framed process early
- Keep your QMS global. MDSAP won’t win a JCA, but it prevents quality surprises across FDA/HC/TGA/PMDA/ANVISA audits and is mandatory in Canada.
Key questions that remain
- Selection mechanics: Which device categories will HTACG prioritize, and how will EU JCAs sync with MDR Expert Panel opinions?
- National implementation friction: Will Germany’s IQWiG/G-BA and France’s HAS fully reuse EU JCAs, or request add-on analyses? (Germany).
- Real-world evidence (RWE): How quickly will EU JCAs embrace RWE standards on par with FDA/CMS? (FDA RWE). CMS RWD protocol template proposal – HARPER+
- Global convergence: AMA’s rollout, MSAC reforms in Australia, CADTH modernization in Canada, and Singapore’s ACE outputs may become the reference web that manufacturers use to triangulate value dossiers alongside EU JCAs. (AU HTA reform) and ADTH/Canada’s Drug Agency methods.